This inventor holds 12 USPTO granted patents and 13 published patent applications, plus 4 CIPO patents and 9 EPO patents. Top assignees: Cellectis, Cellectis S.a.. Active years: 2010-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Paris, FR (2010 - 2016)
- Les Lilas, FR (2018 - 2023)
Company Filing History:
Years Active: 2010-2023
Title: The Innovative Journey of Jean-Charles Epinat in Immunotherapy
Introduction
Jean-Charles Epinat is a prominent inventor based in Paris, France, who has made significant strides in the field of immunotherapy. With a remarkable portfolio of 12 patents, his work primarily focuses on advancing techniques for genetic modifications in primary immune cells, paving the way for safer and more effective therapeutic treatments.
Latest Patents
Among his latest inventions is a groundbreaking patent on sequential gene editing in primary immune cells. This innovative method targets adaptive cell immunotherapy, aiming to reduce the incidence of translocations and cell death. By employing several specific endonuclease reagents simultaneously, Epinat's techniques facilitate genetic modifications at multiple loci. The resultant immune primary cells can be engineered to carry multiple genetic alterations, including triple or quadruple gene inactivated cells. This advancement holds immense potential for therapies derived from a single donor or patient, enhancing the safety and efficacy of immunological treatments.
Career Highlights
Jean-Charles Epinat's career is marked by his contributions to esteemed companies in the biotechnology sector. He has significantly impacted organizations such as Cellectis and Cellectis S.A., where his expertise in innovations and patent applications has driven substantial developments in genetic research and immunotherapy.
Collaborations
Throughout his career, Epinat has had the privilege of collaborating with esteemed colleagues, including Philippe Duchateau and Emmanuel Lacroix. These partnerships have further enriched his research endeavors and have contributed to breakthroughs in the field of adaptive cell immunotherapy.
Conclusion
In summary, Jean-Charles Epinat stands out as a visionary inventor whose work in genetic editing and immunotherapy is creating new possibilities for therapeutic treatments. His dedication to innovation and collaborative spirit exemplify the pivotal role of inventors in advancing medical science and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile